Previous Article | Next Article 
Journal of Virology, February 1999, p. 1293-1301, Vol. 73, No. 2
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The YXXL Sequences of a Transmembrane Protein of Bovine Leukemia
Virus Are Required for Viral Entry and Incorporation of Viral
Envelope Protein into Virions
Kazunori
Inabe,1
Masako
Nishizawa,1
Shigeru
Tajima,1
Kazuyoshi
Ikuta,2 and
Yoko
Aida1,*
Tsukuba Life Science Center, The Institute of
Physical and Chemical Research (RIKEN), Tsukuba, Ibaraki
305-0074,1 and
Section of Serology,
Institute of Immunological Science, Hokkaido University, Kita-ku,
Sapporo 060-0815,2 Japan
Received 20 July 1998/Accepted 31 October 1998
 |
ABSTRACT |
The cytoplasmic domain of an envelope transmembrane glycoprotein
(gp30) of bovine leukemia virus (BLV) has two overlapping copies of the
(YXXL)2 motif. The N-terminal motif has been implicated in
in vitro signal transduction pathways from the external to the
intracellular compartment and is also involved in infection and
maintenance of high viral loads in sheep that have been experimentally infected with BLV. To determine the role of YXXL sequences in the
replication of BLV in vitro, we changed the tyrosine or leucine residues of the N-terminal motif in an infectious molecular clone of
BLV, pBLV-IF, to alanine to produce mutated proviruses designated Y487A, L490A, Y498A, L501A, and Y487/498A. Transient transfection of
African green monkey kidney COS-1 cells with proviral DNAs that encoded
wild-type and mutant sequences revealed that all of the mutated
proviral DNAs synthesized mature envelope proteins and released virus
particles into the growth medium. However, serial passages of fetal
lamb kidney (FLK) cells, which are sensitive to infection with BLV,
after transient transfection revealed that mutation of a second
tyrosine residue in the N-terminal motif completely prevented the
propagation of the virus. Similarly, Y498A and Y487/498A mutant BLV
that was produced by the stably transfected COS-1 cells exhibited
significantly reduced levels of cell-free virion-mediated transmission.
Analysis of the protein compositions of mutant viruses demonstrated
that lower levels of envelope protein were incorporated by two of the
mutant virions than by wild-type and other mutant virions. Furthermore,
a mutation of a second tyrosine residue decreased the specific binding
of BLV particles to FLK cells and the capacity for viral penetration. Our data indicate that the YXXL sequences play critical roles in both
viral entry and the incorporation of viral envelope protein into the
virion during the life cycle of BLV.
 |
INTRODUCTION |
Retroviral envelope (Env) proteins
perform multiple functions that are critical for both viral replication
and pathogenicity and serve as principle targets of humoral and
cellular immune responses (31). They are synthesized as
glycosylated polyproteins that are proteolytically processed by host
enzymes into surface (SU) and transmembrane (TM) subunits during
passage through the Golgi apparatus, and they are selectively
incorporated into budding virions. The SU protein is anchored to the
virion membrane by association with the TM protein, and it appears to
mediate both binding to receptors and determination of the host range
of the virus. The TM protein has three distinct domains: extracellular, membrane-spanning, and cytoplasmic domains. The extracellular domain
binds covalently or noncovalently to the SU protein; at its N terminus
it contains a stretch of about 20 hydrophobic amino acids, which is
designated as the fusion peptide (5, 6, 21, 39, 65) and
which contributes to oligomerization of Env proteins (16, 48, 64,
69). The hydrophobic membrane-spanning domain anchors the Env
protein in the cell and viral membrane (4, 47).
The cytoplasmic tail of the TM protein is processed still further in
murine leukemia virus (27, 29, 35), Mason-Pfizer monkey
virus (M-PMV) (61), and equine infectious anemia virus (52). The cleavage event is catalyzed by a virus-encoded
protease and seems to occur only after the fully assembled virus
particle has been released from the cell (12, 29, 36, 43, 52, 57,
61). In addition to such processing, the cytoplasmic domain is
naturally truncated in a number of cases. Thus, propagation of equine
infectious anemia virus (52), simian immunodeficiency viruses (SIVs) (10, 11, 19, 37, 38, 45), and human immunodeficiency virus type 1 (HIV-1) (59), under some
conditions, selects for mutants with a termination codon in the coding
region for the cytoplasmic domain. It seems that natural selection
favors an extended cytoplasmic domain in some situations and a much
shorter one in others and, furthermore, that in some systems it favors synthesis of an extended form and subsequent removal of the extension by proteolysis. The reasons for the existence of these different forms
are, however, unknown. It seems likely that an understanding of these
phenomena might provide some insight into the function(s) of the
cytoplasmic domain itself. Indeed, introduction of a deletion or a
site-directed mutation into the corresponding coding region has been
shown to cause changes in viral infectivity, the host range of the
virus, the membrane fusion activity, and the level of incorporation of
Env protein into virus particles for HIV-1, murine leukemia virus,
M-PMV, and SIV (7, 13, 20, 25, 34, 49, 50, 53, 70). It seems
likely, therefore, that the cytoplasmic domain contributes to the
regulation of the viral life cycle and viral pathogenicity.
Bovine leukemia virus (BLV), an oncovirus related to human T-cell
leukemia virus types 1 and 2, causes enzootic bovine leukosis, a
disease characterized by a very extended course that often involves persistent lymphocytosis and culminates in B-cell lymphoma
(9). Under experimental conditions, sheep can easily be
infected with BLV and some sheep develop B-cell leukemia/lymphoma at
higher frequencies and after a shorter latency period than cattle
(1, 14). The Env protein of BLV is synthesized as a 72-kDa
precursor that is cleaved to yield a 51-kDa SU protein (gp51) and a
30-kDa TM protein (gp30). gp51 determines the cellular tropism of the virus, whereas gp30 is responsible for anchoring the complex into the
membrane and mediates virus-cell fusion (9, 42). The 58-amino-acid cytoplasmic domain of gp30 contains two overlapping copies of the (YXXL/I)2 motif (where X corresponds to a
variable residue) (51). This motif, designated the
immunoreceptor tyrosine-based activation motif, is found as a pair of
YXXL/I sequences that are separated by seven or eight variable amino
acids, and it contains all the structural information necessary for
signal transduction after the stimulation of T- and B-cell receptors
(18, 67). Studies with chimeric proteins in which the
cytoplasmic domain of CD8-
was replaced by that of BLV gp30 have
shown that the N-terminal (YXXL/I)2 motif participates in
induction of the activation of B cells (3). In addition to
such activity, the two tyrosine residues in the motif also appear to be
involved in infection and the maintenance of high viral loads in sheep
that have been experimentally infected with BLV (70).
However, the mechanism whereby the YXXL sequences of the cytoplasmic
domain control or mediate infection and viral propagation in vivo
remains unclear.
The present study was designed to determine the role in viral
infectivity of the YXXL sequences of gp30. We recently established a
line of cells that is stably transfected with an infectious full-length
molecular clone of BLV, designated pBLV-IF, that produced virus in
sufficient quantities for subsequent infection experiments (32). In this study, we changed either a tyrosine or a
leucine residue to an alanine residue in the YXXL sequences encoded by pBLV-IF by site-directed mutagenesis and we then established stable transfectants that produced the corresponding modified virus. We report
the effects of these mutations on viral propagation in vitro, the
incorporation of Env protein into virions, and the entry of viruses
into host cells.
 |
MATERIALS AND METHODS |
Plasmids and site-directed mutagenesis.
The pBLV-IF plasmid
contains a full-length BLV provirus with two copies of the long
terminal repeat (LTR) and encodes infectious BLV (32). To
generate the mutant proviral DNAs designated Y487A, L490A, Y498A, and
L501A, we introduced site-directed mutations into pBLV-IF by following
the instructions in the manual provided with the ExSite PCR-based
site-directed mutagenesis kit from Stratagene (La Jolla, Calif.)
(66), as shown in Fig. 1. The numbering of nucleotides (nt)
corresponds to that of the complete sequence of BLV reported by Sagata
et al. (55). In brief, 2.3-kb
XhoI-XhoI (nt 4553 to 6888) fragments containing
BLV env sequences were excised from pBLV-IF and subcloned
into pBluescript II KS(
) (Stratagene) to yield pKS-env. A
tyrosine or leucine codon was changed to an alanine codon by PCR with
pKS-env as a template and the following primers: Y487m,
5'-TAGCAAGGCCTGCGCATCAGAATCGGG-3', and Y487a, 5'-CCATCTGCACCAGAGATCTAC-3', for Y487A; L490m,
5'-GCAGATGGTAGCGCGGCCTGATAATC-3', and L490a,
5'-ACCAGAGATCTACTCTCA-3', for L490A; Y498m,
5'-GGGGGAGAGGTGGCTAGCGATCTCTGGTGC-3', and Y498a,
5'-GTCAAACCCGATTAGATCAAC-3', for Y498A; and L501m, 5'-TTTGACGGGGGACGCGTGAGAGTAGATC-3', and L501a,
5'-CCCGATTACATCAACCTCCGA-3', for L501A. The proviral DNA
encoding a protein with two mutated tyrosine residues, Y487/498A, was
also obtained by PCR with the Y487A template and the Y498m and Y498a
primers. In all mutageneses, altered nucleotides are underlined. The
primers were designed to introduce the desired amino acid residue(s),
as well as to introduce or to disrupt the recognition site of a
restriction endonuclease. The XhoI-XhoI fragments
including mutated env sequences were used to replace the
corresponding region of pBLV-IF. To verify the presence of the desired
mutations and the absence of errors due to the use of Taq
DNA polymerase, all of the mutated plasmids were sequenced by the
dideoxy chain-termination method (56) with a
BcaBEST dideoxy sequencing kit (Takara, Otsu, Japan).
The structures of pBLTRCAT, pBLVLTR(U3)-neo, and
pSV-
-galactosidase (Promega, Madison, Wis.) have been described
previously (32).
Cells and transfections.
African green monkey kidney COS-1
cells and fetal lamb kidney FLK cells, the latter of which are
permissive with respect to infection by BLV, were maintained in RPMI
1640 medium supplemented with 10% heat-inactivated fetal calf serum,
penicillin, and streptomycin. The FLK/BLV cell line, which is
persistently infected with BLV, was also used as a positive control in
Western blotting analysis.
For assays of chloramphenicol acetyltransferase (CAT) activity, COS-1
cells (5 × 105) were plated in 10-cm-diameter dishes
the day before transfection, and they were transfected with 5 µg of
wild-type or mutant proviral DNA, together with 8 µg of pBLTRCAT and
2 µg of pSV-
-galactosidase, by the DEAE-dextran method
(58). For transfections for other assays, COS-1 and FLK
cells (5 × 106) were transfected with 50 µg of
either wild-type or mutant proviral DNAs by electroporation in a
cuvette with a 0.4-cm electrode gap and a Gene Pulser II (Bio-Rad Inc.,
Hercules, Calif.) at 260 V and 975 µF.
Cells that constitutively produced mutant BLV were established by
stable transfection with mutant proviral DNAs as described
previously
(
32). In brief, COS-1 cells (5 × 10
6) were
cotransfected with 50 µg of mutant proviral DNA that had
been
linearized with
NotI and 5 µg of
pBLVLTR(U3)-
neo that had
been linearized with
EcoRI by electroporation, as described above,
and stable
transfectants that were resistant to the antibiotic
G418 (1 mg/ml) were
selected.
Assay of viral entry into cells.
To monitor the adsorption
to and penetration of FLK cells by BLV, we performed separate
experiments at 4 and 37°C. Trypsin was used to eliminate virus
particles that had adhered to but not penetrated cell surfaces. Viruses
produced by FLK/BLV cells were concentrated as described above, and
then serial 5-fold dilutions of virus (including reverse transcriptase
[RT] activity of 100,000 cpm) were made in RPMI 1640 medium that
contained 4 µg of Polybrene/ml. A portion of the suspension of
viruses was also heated at 60°C for 1 h as a negative control.
Viruses produced by COS-1 cells that had been stably transfected with
wild-type or mutant proviral DNA were suspended (RT units, 10,000 cpm)
in RPMI 1640 medium that contained 4 µg of Polybrene/ml. FLK cells
that had been plated at 3 × 105 cells per
3.5-cm-diameter dish 1 day previously were incubated with 200-µl
aliquots of the suspension of viruses at 4 or 37°C for 2 h. Then
cells were washed five times with ice-cold RPMI 1640 medium. In
experiments designed to estimate viral penetration, after the first
wash with RPMI 1640, cells were treated with 0.25% trypsin for 5 min
at room temperature. Cells were harvested and washed once with 1 ml of
ice-cold RPMI 1640 medium by mixing for 5 s on a vortex mixer. Cell
pellets were collected by centrifugation at 700 × g
for 30 s and lysed in buffer that contained 2% sodium dodecyl sulfate
(SDS) and 2 mM phenylmethylsulfonyl fluoride. Entire cell lysates after
treatment with trypsin and one-quarter of cell lysates without such
treatment were subjected to Western blotting analysis to monitor levels
of p24 protein.
Other procedures.
Assays for CAT activity, RT activity, and
formation of syncytia, Western blot analysis, immunofluorescence (IF)
microscopy, inoculation of cell-free virus, and serial passage of cells
after transfection with proviral DNA were performed as described
previously (32).
 |
RESULTS |
Three YXXL sequences in the gp30 transmembrane protein of the BLV
infectious molecular clone pBLV-IF and their biological relevance.
In our efforts to clarify the functional role of the YXXL sequences in
the life cycle of BLV, we used the infectious molecular clone pBLV-IF,
which has great potential utility for molecular genetic studies and for
characterization of the biological properties of BLV. First, to verify
the presence of YXXL sequences in gp30 encoded by pBLV-IF, we
determined the nucleotide sequence of the env gene for gp30
that corresponded to the cytoplasmic domain and compared the sequence
with the previously published sequences obtained from nine variants of
BLV (42, 55, 70). The comparison of sequences revealed the
existence of three copies of the YXXL sequences in pBLV-IF and in all
nine variants (data not shown). In addition, the sequence between nt
6211 and 6368 of pBLV-IF was identical to that in the Japanese variant
-BLV (55).
It has been reported that, among the three copies of the YXXL sequence
found in gp30 of BLV, the two N-terminal YXXL sequences
are essential
for signal transduction in cultured cells and that
the third sequence
is not necessary for this activity. Therefore,
we separately mutated
the codons for tyrosine or leucine residues
at positions 487, 490, 498, 501, and 487 plus 498 to the codon
for an alanine residue(s) to obtain
mutant proviral DNAs (Fig.
1). In order
to examine expression of cell-associated viral proteins
and production
of viral particles by the various mutant proviruses,
we transiently
transfected COS-1 cells, which release virus and
strongly express BLV
antigens after transfection with pBLV-IF
(
32). Sixty hours
after transfection, we performed Western blotting,
CAT, and RT analyses
(Fig.
2). Bands corresponding to the structural
proteins of
cell-associated BLV, such as p24, gp30, Pr45
gag,
gp51, Pr70
gag, and
gPr72
env, were detected specifically in the
analyses of all cells that
had been transfected with mutant proviral
DNA by Western blotting
with serum from a BLV-infected sheep (Fig.
2A). The molecular
masses of these
proteins were indistinguishable from those of
proteins detected in
analyses of COS-1 cells that had been transfected
with wild-type
proviral DNA, which served as positive controls.
By contrast, no
specific bands were detected in the analysis with
a control serum from
an uninfected sheep (Fig.
2A). Next, to examine
expression of
trans-activational Tax proteins, we transfected
COS-1 cells
with either wild-type or mutant proviral DNA together
with the reporter
plasmid pBLTRCAT, which harbored the LTR sequences
of BLV upstream of a
gene for CAT, and pSV-

-galactosidase for
normalization of the
efficiency of transfection. The CAT assay
indicated that cells
transfected with all mutant proviral DNAs
synthesized a functional Tax
transactivator at levels similar
to those obtained with wild-type
proviral DNA (Fig.
2B). Moreover,
we examined whether virus particles
were released into the growth
medium of COS-1 cells that had been
transfected with either mutant
proviral DNAs or wild-type DNA by assays
of RT activity. As shown
in Fig.
2C, similar levels of RT activity were
detected in growth
media from all transfectants. Together, these
results demonstrate
that none of the five mutations in the YXXL
sequences affected
the synthesis, processing, and expression of viral
proteins and
the production of viral particles after transfection.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 1.
Relevant sequences of BLV mutants. The amino acid
sequence of the cytoplasmic tail of wild-type gp30 is shown at the top,
and the locations of the two (YXXL)2 motifs are indicated.
The cytoplasmic tail contains three repeats of the YXXL sequence. These
repeats may be arranged as two overlapping (YXXL)2 motifs,
denoted 1 and 2. The positions of substitutions by alanine of leucine
and tyrosine residues described in this study are indicated under the
wild-type sequence. Amino acids identical to those in the latter
sequence are indicated by dashes. The residues in gp30 are numbered
according to reference 55.
|
|

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 2.
Biological features of mutant forms of BLV after
transient transfection of COS-1 cells with mutant proviral DNAs. Sixty
hours after transfection of COS-1 cells with either wild-type or mutant
proviral DNA, Western blotting, CAT, and RT analyses were performed.
(A) Expression of cell-associated BLV structural proteins. Cell lysates
were subjected to SDS-polyacrylamide gel electrophoresis on a 10%
polyacrylamide gel, and then the proteins in the gel were
electrophoretically transferred to a polyvinylidene difluoride membrane
filter (Immobilon; Millipore, Bedford, Mass.). For detection of viral
structural proteins, the membrane was incubated in buffer that
contained either serum from a BLV-infected sheep or control sheep
serum. After washing, the filter was incubated with rabbit antibodies
against sheep immunoglobulin (Ig) G (Cappel, Cochranville, Pa.) as the
second antibody and incubated with horseradish peroxidase-conjugated
antibodies raised against rabbit immunoglobulin (Amersham) as the third
antibody. Positions of the protein markers with molecular masses and of
the BLV structural proteins are indicated. Molecular masses are
expressed in kilodaltons. (B) Expression of functional transactivation
Tax protein. CAT activities of cells transfected with pBLTRCAT, which
harbored the LTR sequences of BLV upstream of a gene for CAT, wild-type
or mutant proviral DNA, and pSV- -galactosidase were determined. (C)
RT activity of a concentrated preparation of viruses that was released
into growth medium. Ten milliliters of the growth medium from each
culture of transfectants was concentrated by ultracentrifugation, and
the virus pellet was suspended in 50 µl of serum-free RPMI 1640 medium. Ten microliters of each concentrated preparation of virus was
then used for the RT assay. Each column and error bar represent the
mean ± standard error of results from three independent
experiments (B and C).
|
|
Serial passage of FLK cells after transient transfection with YXXL
mutant proviral DNAs.
We showed recently that serial passage of
FLK cells after transient transfection with wild-type pBLV-IF results
in the propagation of BLV with sequentially increasing percentages of
BLV antigen-positive cells and progressively increasing numbers of
syncytia (32). To investigate whether the mutant proviral
DNA encoded infectious viruses, we transfected FLK cells with wild-type
proviral DNA or mutant proviral DNA and then monitored the kinetics of
viral replication by serially determining the percentages of cells that expressed BLV antigens, as well as by monitoring the RT activity of
concentrated viruses from the growth media and the formation of
syncytia in cells passaged at 4-day intervals (Fig.
3). The efficiency of transfection seemed
unaffected, with approximately 0.8 to 1.1% of cells being positive for
BLV antigens in all cases 4 days after transfection (Fig. 3A). In FLK
cells transfected with Y487A, L490A, or L501A mutant proviral DNA, the
percentage of cells that expressed viral antigens increased with the
number of passages and approximately 20 to 30% of cells expressed
viral antigens within 20 days after transfection. Similarly, all
proviral DNAs caused an increase in the formation of syncytia and the
production of virus that appeared to spread rapidly though the culture,
as indicated by the increase in RT activity in the concentrated growth media (Fig. 3B and C). The kinetics of replication of the mutant viruses were indistinguishable from that of the wild type in terms of
the increase in the percentage of BLV antigen-positive cells, the RT
activity of the concentrated growth medium, and the number of syncytia.
By contrast, no replication of Y498A and Y487/498A mutant viruses was
detected for 20 days after transfection by any of the three assays
(Fig. 3). Thus, it appeared that replacement by alanine of Y498 in the
second YXXL sequence of gp30 dramatically decreased the efficiency of
both primary infection and secondary infection.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Propagation of mutant BLV in FLK cells after transient
transfection with mutant proviral DNAs. Twenty-four hours after
transfection with wild-type or mutant proviral DNA, cells were replated
at 2.5 × 105 cells per 10-cm-diameter dish and
serially passaged every 4 days in the presence of 4 µg of
Polybrene/ml. Cultured cells were serially passaged at 4-day intervals.
Aliquots of passaged cells were monitored for replication of virus at
the indicated times by indirect IF microscopy of fixed cell smears by
using serum from a BLV-infected sheep (A), RT assay of a concentrated
preparation of the virus that had been released into the growth medium
(B), and monitoring formation of syncytia (C). The data represent those
of a single experiment reproduced in triplicate with similar results.
|
|
Establishment of stable transfectants that harbored YXXL mutant
proviral DNA.
During serial passages of transient transfectants
generated as described above, BLV can spread by both cell-to-cell and
cell-free transmission. To characterize the biological functions of
YXXL sequences in gp30 in viral transmission, it is essential to
establish stable transfectants that can produce sufficient quantities
of mutant BLV for subsequent infection experiments. Therefore, we transfected COS-1 cells with linearized pBLV-IF mutant DNA and pBLVLTR(U3)-neo, which contained the LTR-U3 region of BLV
cloned upstream of the neomycin resistance gene, and then cultured
cells in the presence of G418 as described previously (32).
After G418-resistant colonies had grown up, we individually expanded several colonies within each series of transfectants and examined the
expression of cell-associated BLV antigens by Western blotting (Fig.
4A). Bands corresponding to the
structural proteins of cell-associated BLV, such as p24, gp30,
Pr45gag, gp51, Pr70gag,
and gPr72env, were detected specifically in the
analyses of five mutant proviral DNA-transfected lines by Western
blotting with serum from a BLV-infected sheep. By contrast, no specific
bands were detected in the analysis with a control serum from an
uninfected sheep (data not shown). An RT assay revealed that five lines
of transfectants that harbored mutant BLV released significant amounts
of BLV into the growth medium (Fig. 4C).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 4.
Establishment of cell clones that produced mutant BLV.
COS-1 cells were transfected with linearized wild-type or mutant
proviral DNA in combination with pBLVLTR(U3)-neo.
Twenty-four hours after transfection, cells were replated and cultured
in the presence of 1 mg of G418/ml. From 14 to 28 days after
transfection, several colonies within each series of transfectants were
individually expanded, the expression of BLV structural proteins was
confirmed by Western blotting with serum from a BLV-infected sheep, and
a typical clone for each mutant was then selected. Expression of BLV,
as detected by Western blotting with serum collected from a
BLV-infected sheep and subsequently treated with rabbit antibodies
against sheep immunoglobulin G as the second antibody and horseradish
peroxidase-conjugated antibodies raised against rabbit immunoglobulin
as the third antibody (A), and production of viral particles, as
detected by the RT assay (C), by typical clones are shown (C). Each
column and error bar represent the mean ± standard error of
results from three independent experiments. (B) For quantification, the
intensities of bands (A) were determined with a Bio-Image densitometer
and software (Millipore). Levels of gp51 were normalized for
incorporated Pr45gag levels.
|
|
Transmission of YXXL mutant BLV by cell-free infection.
We
investigated the effects of mutations in YXXL sequences in gp30 on
cell-free infection. Supernatants from cultures of COS-1 cells that had
been stably transfected with either wild-type proviral DNA or mutant
proviral DNA were concentrated by ultracentrifugation, and the RT
activity of the viral suspension in serum-free RPMI 1640 was measured.
An equivalent number of RT units of virus was inoculated into FLK
cells, which are highly susceptible to cell-free infection of BLV
(32). Three and 5 days after inoculation, we examined the
success of infection by indirect IF microscopy, using serum from a
BLV-infected sheep, and by monitoring the formation of syncytia. As
shown in Fig. 5A, among FLK cells that
had been inoculated with wild-type BLV, Y487A, L490A, or L501A mutant
BLV 3 days previously, approximately 1.8 to 3.6% of cells were
positive for BLV antigens. Five days after inoculation, the percentage of positive cells was even higher (3.6 to 4.3%). By contrast, very few
of the FLK cells that had been inoculated with Y498A or Y487/498A
mutant BLV were positive for BLV antigens 3 and 5 days after infection.
Similarly, the numbers of syncytia induced by inoculation with Y498A or
Y487/498A mutant BLV were approximately 4 to 8 times lower than those
of syncytia induced by inoculation with wild-type, Y487A, L490A, or
L501A mutant BLV (Fig. 5B). Thus, the tyrosine residue at position 498 in the second YXXL sequence in gp30 appears to be essential for
successful cell-free transmission of BLV.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 5.
Transmission of mutant BLV by cell-free inoculation. To
concentrate virus particles, growth medium was clarified by
centrifugation at 2,000 × g for 10 min at 4°C and
then the supernatants were filtered (pore diameter, 0.45 µm). The
filtered supernatant was layered on a cushion of 10% glycerol and
centrifuged at 20,000 rpm in an SW28 rotor (Beckman, Palo Alto, Calif.)
for 2 h at 4°C. Pelleted materials were resuspended in
serum-free RPMI 1640 medium. A 200-µl aliquot of a concentrated
preparation of virus (RT units, 10,000 cpm) was used to inoculate FLK
cells (105 cells/3.5-cm-diameter dish) by incubation at
37°C for 2 h in the presence of 4 µg of Polybrene/ml. Cells
were then fed 1.5 ml of complete medium that contained 4 µg of
Polybrene/ml after removal of viruses by aspiration. Twenty-four hours
after inoculation, cells were replated in four 3.5-cm-diameter dishes
and then the expression of BLV (A) and the formation of syncytia (B)
were monitored at three (open columns) and five (shaded columns) days
after inoculation. The expression of BLV was detected by indirect IF
microscopy of fixed cell smears by using serum from a BLV-infected
sheep and subsequently fluorescein isothiocyanate-conjugated rabbit
antibodies against the F(ab')2 fragment of sheep
immunoglobulin G (Cappel). Each column represents the mean of results
from two independent experiments.
|
|
Effects of YXXL mutations on the assembly of Env protein into viral
particles.
The cytoplasmic domain of the transmembrane
glycoprotein gp30 is involved in virus assembly, participating both in
the intracellular transport of the glycoprotein and in incorporation of
the glycoprotein into virions, as well as in entry in the life cycle of
the virus (15, 47, 54, 60). Therefore, we examined whether
the YXXL mutant BLV supported the incorporation of the Env protein gp51 into virions. Before assessing the level of virion-associated Env
proteins in mutant BLV, we first analyzed the levels of cell-associated Env proteins in COS-1 cells that had been stably transfected with each
mutant proviral DNA. The film of the Western blot shown in Fig. 4A was
scanned with a Bio-Image densitometer, and then the relative
intensities of bands that corresponded to structural proteins
Pr45gag and gp51 were quantified (Fig. 4B). The
ratios of intensities of the bands of gp51 and
Pr45gag were similar for each of the five mutant
proviral DNAs and the wild-type provirus. We next analyzed concentrated
virus particles that had been released from COS-1 cells that had been
stably transfected with each of the five mutant proviruses by Western
blotting, using serum from a BLV-infected sheep (Fig.
6A). As in the cases of wild-type virions
and virions from FLK/BLV cells that had been productively infected with
BLV, which served as positive controls, bands corresponding to
structural proteins, such as p24, gp30, Pr45gag,
and gp51, were readily detected in the analyses of all five mutant
virions. However, the relative level of gp51 incorporated into each
preparation of virus varied (Fig. 6B). The ratios of intensities of the
bands of the gp51 and p24 proteins in virions produced by L490A or
L501A mutants were approximately the same as those in virions produced
by the wild-type construct. The gp51 protein of the Y487A mutant was
packaged 1.5 times more efficiently than that of the wild type. By
contrast, virions produced by Y498A and Y487/498A mutants contained
lower relative levels of gp51, namely, 45% of the wild-type level. It
appeared, therefore, that mutation of the tyrosine residue at position
498 in the second YXXL sequence in gp30 reduced the incorporation of
gp51 into virus particles without affecting the synthesis and
processing of Env proteins in COS-1 transfectants. Our findings also
suggest that this phenomenon might be closely related to the
dramatically decreased infectivity that was observed after mutation of
the tyrosine residue at position 498 in the YXXL sequences.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 6.
Incorporation of mutant Env proteins into virions. (A)
Concentrated preparations of virus particles (including RT activity of
20,000 cpm) that had been released from COS-1 cells stably transfected
with wild-type or mutant proviral DNA were fractionated by SDS-10%
polyacrylamide gel electrophoresis and then subjected to Western
blotting with serum from a BLV-infected sheep followed by rabbit
antibodies against sheep immunoglobulin G as the second antibody and
horseradish peroxidase-conjugated antibodies raised against rabbit
immunoglobulin as the third antibody. Viruses released from FLK/BLV
cells, which are productively infected with BLV, were used as a
positive control. Positions of marker proteins with molecular masses
and of BLV structural proteins are indicated. Molecular masses are
expressed in kilodaltons. (B) For quantification, the intensities of
bands on the film shown in panel A were determined with a Bio-Image
densitometer and software (Millipore). Levels of gp51 were normalized
for incorporated p24 levels.
|
|
Effects of YXXL mutations on the adsorption to and penetration of
FLK cells by BLV.
We investigated whether mutations in the YXXL
sequences had any effect on adsorption to and penetration of permissive
FLK cells by the virus. After incubation with BLV at 37°C (for viral penetration) or at 4°C (for viral adsorption), cells were washed to
remove unbound virus before treatment with trypsin. Control cells were
not treated with trypsin. Cells were then lysed, and levels of p24
protein were measured by Western blotting with a monoclonal antibody
against p24 (2). At 4°C adsorption of virus occurs without
subsequent penetration, whereas both viral adsorption to and
penetration of permissive cells are possible at 37°C (40, 68). Treatment with trypsin after the virus has been allowed to
interact with cells eliminates virus particles that have adsorbed to
but not penetrated the cell surface (28, 30). In the absence of trypsin treatment, the amount of p24 protein reflects the amounts of
both virus that has adsorbed to the cell surface and virus that has
already entered cells.
To confirm the validity of the assay that we used to assess viral
adsorption to cells, we diluted virus that had been prepared
from
growth medium of FLK/BLV cells (RT units, 100,000 cpm) from
1:5 to
1:625 in RPMI 1640 medium (Fig.
7A) and
then incubated
the diluted virus with FLK cells at 4°C. Nonspecific
adsorption
of the virus was measured by using FLK cells that had been
incubated
with heat-inactivated virus. As shown in Fig.
7C, in the
absence
of treatment with trypsin after virus-cell interaction, the
amount
of p24 detected depended on the amount of virus in the original
undiluted preparation and in preparations diluted as much as 1:125.
Consistent with the hypothesis that trypsin eliminates virus particles
that have adhered to the cell surface, no p24 was detected when
cells
were treated with trypsin after they had been exposed to
viruses (Fig.
7E). To examine whether adsorbed viruses subsequently
entered cells, we
incubated diluted preparations of viruses, as
described above, with FLK
cells at 37°C. In contrast to the results
obtained at 4°C, the
amount of p24 detected depended on the amount
of virus in undiluted
preparations, even at dilutions as high
as 1:125 in the cases of both
untreated and trypsin-treated cells
(Fig.
7I and G). The amounts of p24
detected in cells that had
been treated with trypsin were approximately
1% of those in trypsin-untreated
cells, which reflected viruses that
had penetrated cells.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 7.
Assay of entry of mutant BLV into cells. Viruses
produced by FLK/BLV cells (RT units, 100,000 cpm) were diluted 1:5 to
1:626 with RPMI 1640 medium that contained 4 µg of Polybrene/ml or
were heated at 60°C for 1 h (A, C, E, G, and I). Viruses
produced by COS-1 cells that had been stably transfected with wild-type
or mutant proviral DNA (RT units, 10,000 cpm) were prepared in RPMI
1640 medium that contained 4 µg of Polybrene/ml (B, D, F, H, and J).
A 200-µl aliquot of a suspension of viruses was incubated with FLK
cells (3 × 105) in a 3.5-cm-diameter dish at 4°C
(C, D, E, and F) or at 37°C (G, H, I, and J) for 2 h. After
virus-cell interaction, cells were washed five times with ice-cold RPMI
1640 medium. Aliquots were subsequently treated with 0.25% trypsin for
5 min at room temperature (E, F, I, and J). Cells were harvested and
washed once with 1 ml of ice-cold RPMI 1640 medium by mixing for 5 s on
a vortex mixer. Cells were pelleted by centrifugation at 700 × g for 1 min and lysed in phosphate-buffered saline that
contained 2% SDS and 2 mM phenylmethylsulfonyl fluoride. A 10-µl
aliquot of the viral suspension (A and B), one-quarter of cell lysates
prepared without treatment with trypsin (C, D, G, and H), and the
entire amounts of cell lysates obtained after treatment with trypsin
(E, F, I, and J) were fractionated by SDS-10% polyacrylamide gel
electrophoresis and then subjected to Western blotting with a
monoclonal antibody against p24 (2) and subsequently
incubated with horseradish peroxidase-conjugated sheep antibodies
against mouse immunoglobulin (Amersham).
|
|
To analyze effects of YXXL mutations on viral adsorption, we incubated
viruses prepared from growth medium of COS-1 cells
that had been stably
transfected with wild-type provirus DNA or
with mutant proviral DNA (RT
units, 10,000 cpm) with FLK cells
at 4°C. As shown in Fig.
7D, when
the virus-cell suspension was
not treated with trypsin, the amounts of
p24 detected for all
five mutant viruses were similar to that for
wild-type BLV (Fig.
7D). When the virus-cell suspension was treated
with trypsin,
bands corresponding to p24 were completely lost in all
cases (Fig.
7F). Furthermore, to analyze the effects of YXXL mutations
on
the entry of viruses into cells, we incubated viruses prepared
from
the growth medium of COS-1 cells that had been stably transfected
with
wild-type or mutant proviral DNA (RT units, 10,000 cpm) with
FLK cells
at 37°C. As shown in Fig.
7H, lower levels of p24 that
became
associated with cells were detected for Y498A and Y487/498A
mutant
viruses without trypsin treatment after the virus-cell
interactions
than for the wild-type virus and the Y487A, L490A,
and L501A mutants.
Likewise, when the virus-cell suspension was
treated with trypsin, the
intensity of the band of p24 was markedly
lower for Y498A and Y487/498A
mutant viruses than for the wild-type
virus and the three other
mutants. Together, these results indicate
that mutation of the tyrosine
residue at position 498 in the second
YXXL sequence of gp30 reduced the
potential for both specific
binding of the virus to the cell surface
and entry into
cells.
 |
DISCUSSION |
Our results lead to two major conclusions. First, the present
study revealed that replacement of tyrosine by an alanine residue at
position 498 in the second YXXL sequence caused a significant reduction
in the infectivity of BLV in both cell-to-cell and cell-free infection.
This result strongly supports the results of Willems et al.
(70), who reported that the tyrosine residue in the second YXXL sequence is essential for successful infection by BLV in vivo.
Second, our results also demonstrated that this mutation affects the
efficiency of entry into cells during an early stage of the virus's
life cycle and the incorporation of Env proteins into virions during
the late stage. Thus, residue Y498 within the YXXL sequence seems
likely to play a critical role in the replication of BLV.
Western blotting of cell-associated viral proteins and virus particles
revealed that although all of the mutant gp30 glycoproteins were
synthesized, processed, and expressed similarly to the wild-type glycoprotein, gp51, they were incorporated less efficiently into the
Y498A and Y487/498A mutant particles than they were into particles of
the wild-type virus and the Y487A, L490A, and L501A mutants. This
result suggests that the cytoplasmic tail of gp30 regulates the level
of incorporation of gp51 into viral particles. It is still unclear how
mutations in the cytoplasmic domain of BLV might affect incorporation
of viral Env proteins. However, there are at least four possibilities.
First, it has been postulated that interaction of specific sequences in
TM protein with Gag proteins is a necessary step for incorporation of
Env proteins into viral particles (24, 25, 44). Such
interactions in retroviruses are supported by the results of studies of
chemical cross-linking of TM protein and matrix (MA) protein in Rous
sarcoma virus (26), the influence of MA mutations on
cleavage of the M-PMV cytoplasmic domain (8), and the
inefficient incorporation of Env proteins in HIV-1 with a mutated MA
protein (20, 71). Thus, the replacement of tyrosine by
alanine at residue 498 in the second YXXL sequence might result in a
less stable association between gp30 and Gag protein, which might play
an important role in the incorporation of gp51 into the virion. A
second possibility is that the conformation of gp30 that is required
for efficient incorporation of Env proteins is disrupted by the
mutation of residue Y498. This possibility is supported by the
following observation: removal of 104 amino acids from the carboxyl
terminus of gp41 of HIV-1 resulted in a mutant virus with significantly
reduced incorporation of Env proteins compared with wild-type virions.
However, the surface expression and the surface anchorage of the gp120
Env protein of HIV-1 were unaffected by this truncation
(72). Spies et al. have demonstrated that a truncated TM
protein of SIV formed more stable SDS-resistant oligomers than did the
full-length TM protein, suggesting that truncation of the cytoplasmic
domain of the SIV Env protein might affect the conformation of the
external domain of this TM protein (62). These results also
imply a third possibility, that the association between SU and TM
proteins on the outside of the membrane is affected by the mutations in
the cytoplasmic domain of BLV. A fourth possibility is that the
cytoplasmic domains of viral glycoproteins are utilized by the virus as
a signal for the incorporation of these glycoproteins into virions,
therefore providing a mechanism for the exclusion of cell surface
proteins (44). For full clarification of the role of YXXL
sequences in the cytoplasmic domain of gp30 in the incorporation of
gp51 into virions, the biochemical characterization of the mutant forms of BLV, i.e., the study of interactions between gp30 and Gag protein and of the structure of gp30 in Y498A and Y487/497A mutant BLV, is essential.
In the present study, we found results indicating that mutant virions
Y498A and Y487/497A, which have significantly reduced incorporation of
gp51 compared to wild-type virions, were noninfectious in FLK cells,
which are permissive with respect to BLV infection. Similarly, previous
studies have suggested that the cytoplasmic domain of TM protein might
make an important contribution to viral morphogenesis and infectivity:
some mutants of HIV-1, SIV, and M-PMV with truncations of the
cytoplasmic domain of TM protein exhibit defective infectivity that is
associated with inefficient incorporation of Env proteins (7, 15,
20, 34, 71). Thus, there appeared to be a correlation between
viral infectivity and incorporation of Env proteins into virions.
Furthermore, it appears that the reduced infectivity of the Y498A and
Y487/498A mutant forms of BLV might be the result of substitution of
alanine for tyrosine at residue 498 in the second YXXL sequence in the cytoplasmic tail of gp30 and its effects on some step(s) after adsorption and/or binding of the virus to cells. Therefore, in addition
to SU protein, TM protein is responsible for successful infection after
entry of the virus into a cell.
The YXXL sequences of gp30 appear to have multiple functions and to be
involved in efficient replication of the virus and development of
leukemogenesis. This hypothesis is supported by the fact that the three
YXXL sequences in gp30 are completely conserved in all of the eight
strains reported to date (42, 55, 70). The potential signal
transduction activity of these sequences (3) also suggests
that Env proteins might function as transducers that mediate abnormal
signals that induce tumorigenesis. It is of interest, in this context,
that latent membrane protein 2A of Epstein-Barr virus, which also
induces human B-cell tumors, has a copy of the (YXXL)2
motif. The immunoreceptor tyrosine-based activation motif in latent
membrane protein 2A blocks signal transduction via B-cell receptors as
a result of constitutive phosphorylation of tyrosine residues within
the motif and an association with Syk tyrosine kinase (22,
23). Moreover, the present study and the results reported by
Willems et al. (70) demonstrate the important roles of these
sequences for successful infection of BLV. Recently, we obtained
evidence suggesting that these sequences might be involved in the cell
surface expression and fusogenic capacity of Env proteins
(33), and several reports have indicated that a YXXL
sequence might be recognized as a tyrosine-containing internalization
motif and might regulate the transport of proteins that contain this
sequence (17, 41, 46, 63). A full understanding of the roles
of YXXL sequences might clarify some of the biological properties of
BLV and the mechanism by which leukemogenesis is induced by BLV.
 |
ACKNOWLEDGMENTS |
We thank Makio Iwashima (Mitsubishi Kasei Institute of Life
Science) and Yoshiyuki Nagai (University of Tokyo) for helpful discussions and Shin-nosuke Takeshima (RIKEN) for kind help with preparation of the manuscript.
This study was supported by Special Coordination Funds for the
Promotion of Science and Technology from the Science and Technology Agency of the Japanese government.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Tsukuba Life
Science Center, The Institute of Physical and Chemical Research
(RIKEN), 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan. Phone: 81 298 36 3522. Fax: 81 298 36 9050. E-mail:
aida{at}rtc.riken.go.jp.
 |
REFERENCES |
| 1.
|
Aida, Y.,
M. Miyasaka,
K. Okada,
M. Onuma,
S. Kogure,
M. Suzuki,
P. Minoprio,
D. Levy, and Y. Ikawa.
1989.
Further phenotypic characterization of target cells for bovine leukemia virus experimental infection in sheep.
Am. J. Vet. Res.
50:1946-1951[Medline].
|
| 2.
|
Aida, Y.,
M. Onuma,
K. Tsukiyama,
Y. Ogawa,
T. Fujieda,
T. Mikami, and H. Izawa.
1987.
Monoclonal antibodies define antigenic regions on the major internal protein p24 of bovine leukemia virus (BLV).
Arch. Virol.
94:315-321[Medline].
|
| 3.
|
Beaufils, P.,
D. Choquet,
R. Z. Mamoun, and B. Malissen.
1993.
The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events.
EMBO J.
12:5105-5112[Medline].
|
| 4.
|
Berman, P. W.,
W. M. Nunes, and O. K. Haffar.
1988.
Expression of membrane-associated and secreted variants of gp160 of human immunodeficiency virus type 1 in vitro and in continuous cell lines.
J. Virol.
62:3135-3142[Abstract/Free Full Text].
|
| 5.
|
Bosch, M. L.,
P. L. Earl,
K. Fargnoli,
S. Picciafuoco,
F. Giombini,
F. Wong-Staal, and G. Franchini.
1989.
Identification of the fusion peptide of primate immunodeficiency viruses.
Science
244:694-697[Abstract/Free Full Text].
|
| 6.
|
Brasseur, R.
1991.
Differentiation of lipid-associating helices by use of three-dimensional molecular hydrophobicity potential calculations.
J. Biol. Chem.
266:16120-16127[Abstract/Free Full Text].
|
| 7.
|
Brody, B. A.,
S. S. Rhee, and E. Hunter.
1994.
Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity.
J. Virol.
68:4620-4627[Abstract/Free Full Text].
|
| 8.
|
Brody, B. A.,
S. S. Rhee,
M. A. Sommerfelt, and E. Hunter.
1992.
A viral protease-mediated cleavage of the transmembrane glycoprotein of Mason-Pfizer monkey virus can be suppressed by mutations within the matrix protein.
Proc. Natl. Acad. Sci. USA
89:3443-3447[Abstract/Free Full Text].
|
| 9.
|
Burny, A.,
Y. Cleuter,
R. Kettmann,
M. Mammerickx,
G. Marbaix,
D. Portetelle,
A. Van den Broeke,
L. Willems, and R. Thomas.
1988.
Bovine leukemia: facts and hypotheses derived from the study of an infectious cancer.
Adv. Vet. Sci. Comp. Med.
32:149-170[Medline].
|
| 10.
|
Chakrabarti, L.,
M. Emerman,
P. Tiollais, and P. Sonigo.
1989.
The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity.
J. Virol.
63:4395-4403[Abstract/Free Full Text].
|
| 11.
|
Chakrabarti, L.,
M. Guyader,
M. Alizon,
M. D. Daniel,
R. C. Desrosiers,
P. Tiollais, and P. Sonigo.
1987.
Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses.
Nature
328:543-547[Medline].
|
| 12.
|
Crawford, S., and S. P. Goff.
1985.
A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins.
J. Virol.
53:899-907[Abstract/Free Full Text].
|
| 13.
|
Denesvre, C.,
C. Carrington,
A. Corbin,
Y. Takeuchi,
F. L. Cosset,
T. Schulz,
M. Sitbon, and P. Sonigo.
1996.
TM domain swapping of murine leukemia virus and human T-cell leukemia virus envelopes confers different infectious abilities despite similar incorporation into virions.
J. Virol.
70:4380-4386[Abstract].
|
| 14.
|
Djilali, S.,
A. L. Parodi,
D. Levy, and G. L. Cockerell.
1987.
Development of leukemia and lymphosarcoma induced by bovine leukemia virus in sheep: a hematopathological study.
Leukemia
1:777-781[Medline].
|
| 15.
|
Dubay, J. W.,
S. J. Roberts,
B. H. Hahn, and E. Hunter.
1992.
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.
J. Virol.
66:6616-6625[Abstract/Free Full Text].
|
| 16.
|
Earl, P. L.,
R. W. Doms, and B. Moss.
1990.
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.
Proc. Natl. Acad. Sci. USA
87:648-652[Abstract/Free Full Text].
|
| 17.
|
Egan, M. A.,
L. M. Carruth,
J. F. Rowell,
X. Yu, and R. F. Siliciano.
1996.
Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein.
J. Virol.
70:6547-6556[Abstract/Free Full Text].
|
| 18.
|
Flaswinkel, H., and M. Reth.
1994.
Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor.
EMBO J.
13:83-89[Medline].
|
| 19.
|
Franchini, G.,
C. Gurgo,
H. G. Guo,
R. C. Gallo,
E. Collalti,
K. A. Fargnoli,
L. F. Hall,
F. Wong-Stall, and M. J. Reitz, Jr.
1987.
Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses.
Nature
328:539-543[Medline].
|
| 20.
|
Freed, E. O., and M. A. Martin.
1996.
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.
J. Virol.
70:341-351[Abstract].
|
| 21.
|
Freed, E. O.,
D. J. Myers, and R. Risser.
1990.
Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.
Proc. Natl. Acad. Sci. USA
87:4650-4654[Abstract/Free Full Text].
|
| 22.
|
Fruehling, S.,
S. K. Lee,
R. Herrold,
B. Frech,
G. Laux,
E. Kremmer,
F. A. Grasser, and R. Longnecker.
1996.
Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.
J. Virol.
70:6216-6226[Abstract].
|
| 23.
|
Fruehling, S., and R. Longnecker.
1997.
The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction.
Virology
235:241-251[Medline].
|
| 24.
|
Gabuzda, D.,
U. Olshevsky,
P. Bertani,
W. A. Haseltine, and J. Sodroski.
1991.
Identification of membrane anchorage domains of the HIV-1 gp160 envelope glycoprotein precursor.
J. Acquired Immune Defic. Syndr.
4:34-40.
|
| 25.
|
Gabuzda, D. H.,
A. Lever,
E. Terwilliger, and J. Sodroski.
1992.
Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins.
J. Virol.
66:3306-3315[Abstract/Free Full Text].
|
| 26.
|
Gebhardt, A.,
J. V. Bosch,
A. Ziemiecki, and R. R. Friis.
1984.
Rous sarcoma virus p19 and gp35 can be chemically crosslinked to high molecular weight complexes. An insight into virus assembly.
J. Mol. Biol.
174:297-317[Medline].
|
| 27.
|
Green, N.,
T. M. Shinnick,
O. Witte,
A. Ponticelli,
J. G. Sutcliffe, and R. A. Lerner.
1981.
Sequence-specific antibodies show that maturation of Moloney leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide.
Proc. Natl. Acad. Sci. USA
78:6023-6027[Abstract/Free Full Text].
|
| 28.
|
Harouse, J. M.,
S. Bhat,
S. L. Spitalnik,
M. Laughlin,
K. Stefano,
D. H. Silberberg, and F. Gonzalez-Scarano.
1991.
Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide.
Science
253:320-323[Abstract/Free Full Text].
|
| 29.
|
Henderson, L. E.,
R. Sowder,
T. D. Copeland,
G. Smythers, and S. Oroszlan.
1984.
Quantitative separation of murine leukemia virus proteins by reversed-phase high-pressure liquid chromatography reveals newly described gag and env cleavage products.
J. Virol.
52:492-500[Abstract/Free Full Text].
|
| 30.
|
Himathongkham, S., and P. A. Luciw.
1996.
Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells.
Virology
219:485-488[Medline].
|
| 31.
|
Hunter, E., and R. Swanstrom.
1990.
Retrovirus envelope glycoproteins.
Curr. Top. Microbiol. Immunol.
157:187-253[Medline].
|
| 32.
|
Inabe, K.,
K. Ikuta, and Y. Aida.
1998.
Transmission and propagation in cell culture of virus produced by cells transfected with an infectious molecular clone of bovine leukemia virus.
Virology
245:53-64[Medline].
|
| 33.
| Inabe, K., S. Tajima, and Y. Aida. Unpublished
data.
|
| 34.
|
Johnston, P. B.,
J. W. Dubay, and E. Hunter.
1993.
Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells.
J. Virol.
67:3077-3086[Abstract/Free Full Text].
|
| 35.
|
Karshin, W. L.,
L. J. Arcement,
R. B. Naso, and R. B. Arlinghaus.
1977.
Common precursor for Rauscher leukemia virus gp69/71, p15(E), and p12(E).
J. Virol.
23:787-798[Abstract/Free Full Text].
|
| 36.
|
Katoh, I.,
Y. Yoshinaka,
A. Rein,
M. Shibuya,
T. Odaka, and S. Oroszlan.
1985.
Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity.
Virology
145:280-292[Medline].
|
| 37.
|
Kodama, T.,
D. P. Burns,
H. W. Kestler III,
M. D. Daniel, and R. C. Desrosiers.
1990.
Molecular changes associated with replication of simian immunodeficiency virus in human cells.
J. Med. Primatol.
19:431-437[Medline].
|
| 38.
|
Kodama, T.,
D. P. Wooley,
Y. M. Naidu,
H. W. Kestler III,
M. D. Daniel,
Y. Li, and R. C. Desrosiers.
1989.
Significance of premature stop codons in env of simian immunodeficiency virus.
J. Virol.
63:4709-4714[Abstract/Free Full Text].
|
| 39.
|
Kowalski, M.,
J. Potz,
L. Basiripour,
T. Dorfman,
W. C. Goh,
E. Terwilliger,
A. Dayton,
C. Rosen,
W. Haseltine, and J. Sodroski.
1987.
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.
Science
237:1351-1355[Abstract/Free Full Text].
|
| 40.
|
Krichbaum-Stenger, K.,
B. J. Poiesz,
P. Keller,
G. Ehrlich,
J. Gavalchin,
B. H. Davis, and J. L. Moore.
1987.
Specific adsorption of HTLV-I to various target human animal cells.
Blood
70:1303-1311[Abstract/Free Full Text].
|
| 41.
|
LaBranche, C. C.,
M. M. Sauter,
B. S. Haggarty,
P. J. Vance,
J. Romano,
T. K. Hart,
P. J. Bugelski,
M. Marsh, and J. A. Hoxie.
1995.
A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells.
J. Virol.
69:5217-5227[Abstract].
|
| 42.
|
Mamoun, R. Z.,
M. Morisson,
N. Rebeyrotte,
B. Busetta,
D. Couez,
R. Kettmann,
M. Hospital, and B. Guillemain.
1990.
Sequence variability of bovine leukemia virus env gene and its relevance to the structure and antigenicity of the glycoproteins.
J. Virol.
64:4180-4188[Abstract/Free Full Text].
|
| 43.
|
Menendez, A. L.,
D. Gotte, and S. Oroszlan.
1993.
Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme.
Virology
196:557-563[Medline].
|
| 44.
|
Metsikko, K., and H. Garoff.
1990.
Oligomers of the cytoplasmic domain of the p62/E2 membrane protein of Semliki Forest virus bind to the nucleocapsid in vitro.
J. Virol.
64:4678-4683[Abstract/Free Full Text].
|
| 45.
|
Naidu, Y. M.,
H. W. Kestler III,
Y. Li,
C. V. Butler,
D. P. Silva,
D. K. Schmidt,
C. D. Troup,
P. K. Sehgal,
P. Sonigo,
M. D. Daniel, and R. C. Desrosiers.
1988.
Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac.
J. Virol.
62:4691-4696[Abstract/Free Full Text].
|
| 46.
|
Ohno, H.,
J. Stewart,
M. C. Fournier,
H. Bosshart,
I. Rhee,
S. Miyatake,
T. Saito,
A. Gallusser,
T. Kirchhausen, and J. S. Bonifacino.
1995.
Interaction of tyrosine-based sorting signals with clathrin-associated proteins.
Science
269:1872-1875[Abstract/Free Full Text].
|
| 47.
|
Perez, L. G.,
G. L. Davis, and E. Hunter.
1987.
Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions.
J. Virol.
61:2981-2988[Abstract/Free Full Text].
|
| 48.
|
Pinter, A.,
W. J. Honnen,
S. A. Tilley,
C. Bona,
H. Zaghouani,
M. K. Gorny, and S. Zolla-Pazner.
1989.
Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.
J. Virol.
63:2674-2679[Abstract/Free Full Text].
|
| 49.
|
Ragheb, J. A., and W. F. Anderson.
1994.
pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: implications for the role of the R peptide and p12E TM in viral entry.
J. Virol.
68:3220-3231[Abstract/Free Full Text].
|
| 50.
|
Rein, A.,
J. Mirro,
J. G. Haynes,
S. M. Ernst, and K. Nagashima.
1994.
Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein.
J. Virol.
68:1773-1781[Abstract/Free Full Text].
|
| 51.
|
Reth, M.
1989.
Antigen receptor tail clue.
Nature
338:383-384[Medline].
|
| 52.
|
Rice, N. R.,
L. E. Henderson,
R. C. Sowder,
T. D. Copeland,
S. Oroszlan, and J. F. Edwards.
1990.
Synthesis and processing of the transmembrane envelope protein of equine infectious anemia virus.
J. Virol.
64:3770-3778[Abstract/Free Full Text].
|
| 53.
|
Ritter, G., Jr.,
M. J. Mulligan,
S. L. Lydy, and R. W. Compans.
1993.
Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain.
Virology
197:255-264[Medline].
|
| 54.
|
Rose, J. K., and J. E. Bergmann.
1983.
Altered cytoplasmic domains affect intracellular transport of the vesicular stomatitis virus glycoprotein.
Cell
34:513-524[Medline].
|
| 55.
|
Sagata, N.,
T. Yasunaga,
J. Tsuzuku-Kawamura,
K. Ohishi,
Y. Ogawa, and Y. Ikawa.
1985.
Complete nucleotide sequence of the genome of bovine leukemia virus: its evolutionary relationship to other retroviruses.
Proc. Natl. Acad. Sci. USA
82:677-681[Abstract/Free Full Text].
|
| 56.
|
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467[Abstract/Free Full Text].
|
| 57.
|
Schultz, A., and A. Rein.
1985.
Maturation of murine leukemia virus env proteins in the absence of other viral proteins.
Virology
145:335-339[Medline].
|
| 58.
|
Seed, B., and A. Aruffo.
1987.
Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.
Proc. Natl. Acad. Sci. USA
84:3365-3369[Abstract/Free Full Text].
|
| 59.
|
Shimizu, H.,
F. Hasebe,
H. Tsuchie,
S. Morikawa,
H. Ushijima, and T. Kitamura.
1992.
Analysis of a human immunodeficiency virus type 1 isolate carrying a truncated transmembrane glycoprotein.
Virology
189:534-546[Medline].
|
| 60.
|
Simpson, D. A., and R. Lamb.
1992.
Alternations to influenza virus hemagglutinin cytoplasmic tail modulate virus infectivity.
J. Virol.
66:790-803[Abstract/Free Full Text].
|
| 61.
|
Sommerfelt, M. A.,
S. R. Petteway, Jr.,
G. B. Dreyer, and E. Hunter.
1992.
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage.
J. Virol.
66:4220-4227[Abstract/Free Full Text].
|
| 62.
|
Spies, C. P.,
G. Ritter, Jr.,
M. J. Mulligan, and R. W. Compans.
1994.
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain.
J. Virol.
68:585-591[Abstract/Free Full Text].
|
| 63.
|
Trowbridge, I. S.,
J. F. Collawn, and C. R. Hopkins.
1993.
Signal-dependent membrane protein trafficking in the endocytic pathway.
Annu. Rev. Cell Biol.
9:129-161.
|
| 64.
|
Tucker, S. P.,
R. V. Srinivas, and R. W. Compans.
1991.
Molecular domains involved in oligomerization of the Friend murine leukemia virus envelope glycoprotein.
Virology
185:710-720[Medline].
|
| 65.
|
Voneche, V.,
D. Portetelle,
R. Kettmann,
L. Willems,
K. Limbach,
E. Paoletti,
J. M. Ruysschaert,
A. Burny, and R. Brasseur.
1992.
Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells.
Proc. Natl. Acad. Sci. USA
89:3810-3814[Abstract/Free Full Text].
|
| 66.
|
Weiner, M. P.,
G. L. Costa,
W. Schoettlin,
J. Cline,
E. Mathur, and J. C. Bauer.
1994.
Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction.
Gene
151:119-123[Medline].
|
| 67.
|
Weiss, A., and D. R. Littman.
1994.
Signal transduction by lymphocyte antigen receptors.
Cell
76:263-274[Medline].
|
| 68.
|
Weiss, R.
1982.
Experimental biology and assay, p. 209-260.
In
P. Weiss, N. Teich, H. Varmus, and J. Coffin (ed.), RNA tumor viruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 69.
|
Wild, C.,
J. W. Dubay,
T. Greenwell,
T. Baird, Jr.,
T. G. Oas,
C. McDanal,
E. Hunter, and T. Matthews.
1994.
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex.
Proc. Natl. Acad. Sci. USA
91:12676-12680[Abstract/Free Full Text].
|
| 70.
|
Willems, L.,
J. S. Gatot,
M. Mammerickx,
D. Portetelle,
A. Burny,
P. Kerkhofs, and R. Kettmann.
1995.
The YXXL signalling motifs of the bovine leukemia virus transmembrane protein are required for in vivo infection and maintenance of high viral loads.
J. Virol.
69:4137-4141[Abstract].
|
| 71.
|
Yu, X.,
X. Yuan,
Z. Matsuda,
T. H. Lee, and M. Essex.
1992.
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.
J. Virol.
66:4966-4971[Abstract/Free Full Text].
|
| 72.
|
Yu, X.,
X. Yuan,
M. F. McLane,
T.-H. Lee, and M. Essex.
1993.
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions.
J. Virol.
67:213-221[Abstract/Free Full Text].
|
Journal of Virology, February 1999, p. 1293-1301, Vol. 73, No. 2
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.